Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus LAMIVUDINE.
EMTRICITABINE vs LAMIVUDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase and hepatitis B virus polymerase via incorporation into viral DNA, causing chain termination.
200 mg orally once daily, typically in combination with other antiretroviral agents.
150 mg orally twice daily or 300 mg orally once daily; for HIV-1 infection, 300 mg once daily or 150 mg twice daily; for hepatitis B, 100 mg orally once daily.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateLamivudine + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Lamivudine."
Clinical Note
moderateLamivudine + Ranolazine
"The serum concentration of Ranolazine can be increased when it is combined with Lamivudine."
Clinical Note
moderateLamivudine + Bupropion
"The serum concentration of Bupropion can be increased when it is combined with Lamivudine."
Clinical Note
moderateLamivudine + Rolapitant
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 5-7 hours in adults; prolonged to 20-35 hours in patients with creatinine clearance <30 mL/min, necessitating dose adjustment
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Renal: approximately 70% of the dose excreted unchanged in urine via glomerular filtration and active tubular secretion; biliary/fecal: minimal, less than 5%
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The serum concentration of Rolapitant can be increased when it is combined with Lamivudine."